OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-12-31-accounts

Oo¢usignEn%elope ID." 8fK8ED2F.F7BMgfUo37￿98l IC68D562 Registered number: 12099857 Charity number: 1200765 TREAT-NMD Alliance Ltd Annual report 31 December 2025 IDIIIIIII AFBN¢A)YYt 186 COMPANIES HOUSE

Do¢u519Th Envelope ID.. BoC8ED2F*78M￿?E98l1C6O1Afj2 TREAT-NMD Alliance Ltd Contents Page Referen￿ and administrative detsils Trustees. report Truslees, responsibilities statement Independent auditors. report on the finanaal statement$ lo the members of TREAT-NMD Alliance 10-13 Consolidated statement of financial aclivil 14 Consolidated balance sheet 15 Charity balance sheet 16 Cor>solidated ststemenl of cash flNs 17 Note5 to the financial slalements 18-35

DouJ5¥Jn Envelope10.. &￿8E02F￿2￿￿￿037Es811c68￿2 TREAT-NMD Alliance Ltd Reference and administrative details Period ended 31 December 2025 Trustees Prof Volker Wilhelm Slraub Dr James Joseph Dvwling (resigned 2 June 2025) Prof and t>ean Kanneboyina Nagaraju Dr Kathryn Rae Wagner {aprknnted 2 June 20251 Company registered number 12099857 Charity registered number 1200765 Reglsterèd offl¢e CIO Womble Bond Diekinson (UK) LLP The Spark. Oraymans Way Newcastle Helrx Neweasue upon Tyne. Englarh NE4 5DE Company secretary David Allison Chief exKudvg officer David Atlison Independent auditors UNW LLP Chartered Accountants Cityg*e Sl James. Boulevard Newcastte upon Tyne NE14JE Page 1

OorJJsiqn ErNelope ID.. BOc8ED2F-F7B>8KA4o37￿9￿11C880562 TREAT.NMD Alliance Ltd Trustee$, report Period ended 31 December 2025 The trustees present their annual report together %Mih the audrted ffinanoal statements of the chaTily for the 17 month period 011 August 2024 to 31 December 2025. The annual report serves the purposes of both a Iruslees. report and a directors, report under company law. The trustees confirm that the annual report and financial statements of the chantable company comply wrth the current slalutory requirements, the requirements of the charitable company's govefning document and the provisions of the Statement of Recommended Practice {SORP} applicable to charrt￿S preparing their accounts in accordance wrth the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS102} (effectrve 1 January 2019). Since the group and the charty qualrfy as small under seclh)n 383 of the Crynpanies Act 2006, the group strategi¢ report required of medium and large companEs under the Companie$ Act 2006 (Strategic Report and D1￿Clor$, Report) Regulations 2013 has been omrtled. Oblectivos and acllvltles Policies and objectives The charitys object$ are speCif￿ty restricted lo the folb)wing." TREAT-NMD Alliance Ltd exists for the public benefft lo advance the health of the public arKJ, ancillary lo this. to advance the education of the public, principalty, bLrt not excluswety, by. promoting research into new Medic￿ thefapie5 for the treatment of neuromuscular and other rare diseases provided that the useful resutts of such research are disseminated to the public al large., educating medical practrtioners. scientists and other profess￿n81$ In the care and t￿atment of persons with neuromuscular and other rare diseases" supporting and thereby relievir¥J the needs of and improving the quality of lives of persons with neuromuscular and olher rare diseases land their families and carers) by educating about and promoting aceessibilty lo treatment or by such other means as the trusiees shall see fft", and raising awareness of li￿lUdIng devebpments in treatment options for) neuromuscular and other rare disease5. Strategies for achieving objeclives The strategies for achieving the group objects can be summarised by the TREAT-NMD Aims.. Inform. Connect, Advance The activities of the group can be clustered around and summarwl by each of these words. The actiwlies of TREAT-NMD Allan￿ Ltd centre around the provision of education and training events. TREAT-NMD SeThices Ltd aclNil*s infomi healthcare professionals as to the impact neuromuscular diseases have on patients and their families. h¢)w best lo diagnose Ihe5e di5e8ses. the current best advice regarding pathwayB of Care and provide details of emerging treatments. Famity Guides help newty diagnosed patients to understand Iheir disease and what support is available. TREAT-NMD SeThKes Ltd provKles a range of wnmercial Ser¥￿S a¢r05S the drug devebpmenl pipeline that infom, conneet and advance treatmenls to patients by derisking Clinical trials and sharing best practice, providing data and running projects lo support studies, cFinieal trial design, and post authorisalion long term follow up. and by running sponsofed events. most notabty the biennial TREAT￿MD Conference that brings patients, researchers. xademi¢s and industry together to share information, connect stakeholders and Communrties, and to raise awareness of issues and emerging solutions. Hawng given due consxleralion to the Charty Comrnission guidan￿ relatiru to publi¢ benefit. the Iruslees are satisfied Ihal the actiwknes of the TRBAT-NMD group continue to deliver sub$lantial benefits in line with the chartys objects. Page 2

DorJJ$wJn Env￿optI0.. gOC8ED2F.F78MU8037.E9811C68D562 TREAT-NMD Alliance Ltd Trustees, report Icontinued) Period ended 31 December 2025 Achlevements and performance Main achievements To best progress the aims and objectives of the TREA T-NMD Global Nelwork rt was determined that, in addition to the commercial trading entity TREAT-NMD Services Ltd. a TREAT￿MD group structure would be established wrth a UK regisleied charity, TREAT-NMD AIIK4n¢e Ltd. In addition to establishing a Board of Trustees of TREAT-NMD Allian￿ Ltd from the Gbbal Netsvork, an advis¢yy commtttee- NMDAC was established to provide insight as lo global NMD priorities. A key achievement of this year saw TREAT4IMD SeNices Ltd progress in the Grant Agreement lo deliver key milestones of the PaLaDln Project. Thi$ sees TREAT-NMD as the Scienlffic Coordinator for a 9-partner consortium with funding coming from the European CommissK)n IIHI Call 31 and Innovate UK (Grant Guarantee Schemel. In 2025 the General Assembly ￿￿$ hekl in Rome. required to 8ngage patients and clinicians in the development of the Inlera¢tium. The Global Registry Nebvork held its Annual Curators Meeting in Milan in February 2025 and this saw more than 40 registry curators gather lo discus5 how best lo contribute to drug develcpment through dats provision wth an emphasis on dats qualty. The data qualty management tool devebped by TREAT-NMD was demonstrated and received excel￿nI feedback. Input into key deliverables of the PaLaDln project were discussed wth the global curators for input and verification of design processes. To further estsblish ccfftct foundations. the Compliance team have led the efforts lo gain IS027001 continued acefeditalK>n. This team will support the growng activty of TREAT-NMD group in data provision and help establish the necessary qualrty framework. The Data and Scientific Projeets teams have been working wrth Key Opinion Leaders to leverage the Global Registry Network data to SLtpport a Trmde range of data prwects al various stages of the drug development pipeline. The use of the nefv￿rt(. its govemanee. the data, the technology and the qualty framework were described lo the European Med￿lneS Agency IEMA) in the TREAT-NMD Services Ltd submission to the E￿ Qualification process undertaken during last year and this remains an area of ongoing pro9￿SS and focus. The status of potential NMD treatments is maturing and this has led to multiple authorisalions by the regulator and a greater number of trealments advancing towards aulh0risal￿}n. This is resurting in a growing demand for high quality, patient level Real World Data to SLtpport applications and their long term follthv up. This is a real challenge globally for providers of Real Worfd Ev￿ence IRWEI and the TR&4T-NMD group are no exceptions. Overseeing a range of Data Qualty Improvement Inrtiatives i% the top priority for TGDOC - The TREAT-NMD Global Data Over5ighl COmrn￿ee. The PaLaDln Project wll see the delwery of updated datasets in Facioscapulohumeral Muscular Dystrophy IFSHDI and Myotonic D￿trophY moving forwards. A wide range of events were delNered by TREAT44MD throug1￿Ut the year I￿lUdi1￿￿ a LGMD Maste￿laSS in Montreal March 2025, patient Becker Masterelass in September 2025. Duchenne Muscular Dystrophy IDMDI and Spinal MusoJLryr Alrcphy ISMA) PAaslerclasses in Prague Juty 2025 as well as our Industry Day. A range of educational pr¢¥ects have been pro9￿$sed wtyth the DMD Earty Diagnosis, and the LIM￿1rdle Muscular Oystrophy {LGIAD) Famity Guide most notable. Page 3

OocusigTh Env•knw ID. 8OC8ED2F-F7B>8￿A￿037￿9B11c68D TREAT-NMD Alliance Ltd Trustses, report (contlnued) Period ended 31 December 2025 Achlevements and perfomiance Icontlnuedl Plans for future periods Having established the TREAT-NMD group slruclure, at the end of 2025 a Governanee Review was undertaken with external advisors the re$uA of which has led to establishing Non Execulrve Board va￿ncieS which will be add￿ssed in 2026. Followng on from our successful to the European Commissb)n IHI Call 3. the PaLaDln Project needs to move beyond estsblishing the govemance and funding lo devek)p the specffication for the central plattorm, the Inleracb"um, and ensuring that the consortium partners actNities ale well aligned. The input of the Extemal AdMscAy Board and the Ethics Board wll be fvndamental to ensuring that the key prIOr￿e$ are progressed. An i￿reasing focus on Data wll align well vith the Regulalors. desire to rnake better use of Real-world Data. This will see TREAT-NMD continue to develop technologtsl solutions to assist the g￿bal registry ne￿Ork in continuous improvement arKI stronger links our growing online edvcatK)n offerings lo increase regulator and industry assurance. Moving fO￿ardS. TREAT-NMD will be aiming to introduce a standard neuromuscular disease dalasel to better addiess industy needs and to uttimatety gain EMA Qualification across a range of diseases induding SMA, DMD and LGMD. Strategic relal#)nships remain key lo TREAT-NMD. Although a Gk)bal nelwork. Ikke the pharmaceutical industry 8s a whole, TREAT-NMO'S emphasis has tradrtionally been in Europe and North America. Moving forwards, the organisalion is keen to increase ils presence gktlally and to be more inclusive where ils support Can have positive impad. Financial review Financial performance The Group changed its &eounting reference date during the period. These financial statements therefore cover an extended accounting peri¢xl of 17 months, from 1 August 2024 to 31 December 2025. aligning the Group's repo￿.n9 cycle with the calendar year. Because the current period spans 17 months. rt is not directy comparable with the preceding 12-month period. and comparative figures should be read wth that in mind. To assist readers, an analysi$ of the resutt be￿n the fv40 conslituenl peri￿$ is set out in Ta￿e 3. Budget figures represent the budget approved by the Board for the full extended period. All fjgures ar9 Stated in pounds sterling and rounded to the nearest pound. Figures in brackets denote negatwe amounts oi adverse variances. Overview of the result The Group recorded total income of £3,094,584 and total expendrtuie of £3.104.880 for the 17-monlh period, resulting in a net defKit 01 £10.296. This deficrt is ststed after charging exceptional costs of £11,907 and a depreciation ¢haige of £3.201. Excluding these rtems. the Group's UnderI￿n9 operating result was a surplus of £4.812. which is £4.723 ahead of the budgeted resuh of £89 (Break*venl- The leadership team consider the Group to have perfoTrned broadly in line with budget al the operating level, nO￿lth5tandpng a lower than budget income in lunding inccvne whith was subslanlialty offset by Ioy•ver direct delivery costs. Page 4

Doc￿51qn Enwlope ID.. B0C8ED2F￿7BwA￿O37￿g8l1￿DS62 TREAT-NMD Alliance Ltd Trustees. report (continued) Period ended 31 December 2025 Table l - Summary of f#)antial perfmffta￿ for the 17.month pernd ended 31 December 21Y25 Actual 11 month5 Budget Variance Varrance Furthg incon 3,￿0,563 3A59,291 1372.7281 (JO.81 Interest rece￿able 8,021 8,021 Totsl incom (364.71171 (Il5} Expenthlu Direct w(ryert and (klfvwi v)5ts 1375.( 4343fj6 31.6 Supw>rtaKI th1Thstratbve r05ts 2.164185 2.W,142 180.thts) 13.8 Total ey4)eralitsJTe Vwiante perrentsr$4reethwe5%ed rEtsti¥elo bu¢et forrred fj in •OMce. Income Total income for the period was £3.094.584, compnsing lunding income of £3.086.563 and interest receNable of £8,021. Funding income was £372,728, or 10.8%. below the budget of £3,459.291. The principal reasons for the variance were". timing of milestone recc¥Jnrth a delayed contract stsrt Interest receNable of £8.021 was eamed on cash balances hekl on deposit during the period and was not separalety budgeted. Expenditure Totsl expenditure for the period was £3.104,880 against a budget of £3.459.202. an underspend of £354,323 110.2°h}. Direct projecl and delivery costs Direct costs of £940.694 were below budget This underspend is closely linked to the lower reported total in fijnding income, refleth'ng the variable nature of project delivery costs. which are incurred as funded aetivily is Lbndertaken. Support and adminisbative costs Support and administrive costs of £2.164.185 exceeded budget by 3.8%. E¥ceplional wsls Exceptional eosls of £11.907 were Ir￿rred during the perK)d. They are one off. non-recurring. and not linked to in year operations. Result for the pefiod The leadership team also monilor the underI￿n9 operating result, which excludes exceptional and nonrycash items. as an indicator of the sustainability of ongoing 0per*"Crf￿. Page 5

DocusKJn En%t0pe ID.. 80c8ED2F.F7B34￿7.E9811C6OO2 TREAT-NMD Alliance Ltd Trustees, report (continued) Period ended 31 December 2025 Table 2- Remft(iliatton of the statutory rewft to thE Undert￿ry operating result Amount 1£) Ilet forthe perJd (10.296) Add back". exceptlonal costs IL907 Add back.. dePre0a￿On cha￿￿ 3,201 unde￿ing operatfn8 reA 4.812 Budgeted result Favoufable Varian￿ a8atnst I￿￿get 4.723 The undthwngoFeratir¢Ie5￿t bnota Th￿￿￿d￿hr￿￿I￿rtheth3ntie5 SORP 15 wesented a5 wlplernent￿Inf￿rrnatsD Analysis by constituent period The table below analyses the resuh of the exlended accounting period between the fve nx)nths lo 31 December 2024 and the tsvefve months lo 31 Detember 2025. The deficrt arose entirely in the earlier fwewmcmth period,. the Group relurned a surplus in the Ca￿ndar year 2025. Table 3- Result analysed betweeTrlhe fl¥e monthslo 31 Decefft￿ 2024 and the yearto 31 Dècember 2025 Aus- Dec 2024 IS monthsl Jan- Dec 2025 112 month5) TotAI 117 monlhsl Fundlng Income 637.032 2.449.531 31￿&.56￿ InteFe51 ￿(￿l¥able 1797 5.224 Total income 1454.755 3m4.584 Dlrert projert and deli¥ery costs (396.0931 1544.6021 1940.695) support and adminislratrwe cos15 {fa7A30) 11,526,355) 12.164.185) Total expendilure IL0333231 (2J170.9571 P4et (der￿lt / income 1394.0941 The f￿￿K￿th period to 31 Decernkn 2024carried a di5￿c￿￿ale Sh￿ of 5￿port athnirsbalre costs relatibrtolthe fundir¥ ihrvrne rEfWi5ed iftll*xerfthiths. reAeLtsEthe s￿sOnal profile. Page 6

Docu5i9rn Enveltspe ID." B￿8EO2F-FI8mSrA-eO37￿81lc6fiO562 TREAT-NMD Alliance Ltd Trustees, report (continued Period ended 31 December 2025 Golng concern After making appropriate enquiries, the trustees have a reasonable expectation that the company has adequate resources to continue in operabonal existen￿ for the foreseeab￿ future. For this reason, they continue to adopt the going concern basis in preparing the ffinancial stslements. Further details regarding the adoption of the going concem basis can be found in the accounting poli¢4e$_ Resenf&s policy Th8 reserves policy for TREAT-NMO Ltd ¢￿tInUeS to build reserves to support the charily's objectives and to ensure the group's t)bjeclives can be delwered rf the￿ were any short term reductions in extemal funding, lo support investments and actmties in the Netsvork. This involves ensurirsg that al least 6 months salary cosls are available al each year end period (excluding the grant covered fixed temi personnel), which totals £440,000. Al the end of the period. free reserves amounted to £808.623 which is above the largeled level. Teflecling the investment in the PaLaDln project expected over the coming years. The Iruslees are satisfied with the year end position. Structure. govefnance and management Constitution TREAT-NMD Alliance Ltd is registered as a charitable wnpany limited by guarantee with company number 12099857 and registered Charity number 1200765. 11 is goveme(J by Art￿leS of Association adopted by 5peeial resolution dated 7 November 2023. Methods of appointment or e￿CtIOn of trustees No formal policy is in place for the appointrnenl or election of trustees. Trustees are recruited and appointed based upon the kntrwledge, skills and experien￿ judged lo be necessary and appropriate for the group. Trustees are recruited from within the Global Ne￿ork for disease spe¢thc kr￿wledge and from wider circles for relevant business knowledge. Newcastle UnNersty is entitled lo appoint one trustee to TREAT-NMD Alliance Ltd. New apwnlments are appToved at Board level. Organlsational slructurg and docisionwmaking policies The managernenl of the chartty is the responsibility of the tnjstees who are elected under the terms of the conslitLrtion, but the effective day lo day management is delegated to the Chief Execytive and staff wilhin the group. Policies adopted for the Induction and training of trustees No formal policies a￿ in place for the inductNJn and training of trustees. New trustees are provided with key documents and policies, including terms of reference and expectab"ons. Trustees are ab￿ to have indudion meelings wrth key staff. including the Chief Executive. rf required. Risk manag8rnent The trustees have high ￿Ve1 oversight of risks wrth the higher risk items on the Risk Register revwed quarterly al the Boald meetings of both charity and trading companies. The detailed risk management in operations and finance is managed on a day-ltrday basis by the Chief Execuknve and senior staff in the group. Page 7

Doeusv4Th El￿￿)￿* ID" Boc8E02F￿7B￿e￿A-OO37￿g811c6sD562 TREAT-NMD Alliance Ltd Trustees, report (continued) Period ended 31 December 2025 Disclosure of information to auditors Each of the persons who are trustees al the time when this trustees, report is approved has confirmed that: so far as that trustee is aware. there is no re￿an1 audrt information of whieh the charitable group's audrtor5 are unaware, and that IrLbslee has taken all the steps that ought lo have been taken as a trustee in order to be aware of any relevanl audit information and to establish that the chari(able group's auditors are aware of that inf0mat￿. Auditors The auditors, UNW LLP, have indicated their willingness lo continue in offf￿. The designated trustees will propose a motion reappointing the auditors at a meeting of Ihe Iruslees. Approved by order of the members of the board of Iritstees on 24 September 2026 and signed on their behalf by.. Prof Volker Wilhelm Straub Director Page 8

Do¢uswJn Efi￿Fe ID." BCC8ED2F.F78MKA4037E9811C68D562 TREAT-NMD Alliance Ltd Statement of trustees, responsibilities Period ended 31 December 2025 The trustees (who are also the director5 of the charty for the purposes of company Lwl are responsible for preparing the truslees. report and the financial ststements in accordance with applicable law and United Kingdom Accounting Standard5 (Unrted Kingdom Generally Aceepled Accounting Practicel. Company law ￿qUI￿$ the trustees lo prepare financial ststements for each financial year. Under company law, the trustees musl not approve Ihe financial ststements unless they are satisfied that they give a true and fair view of the slate of affairs of the group and the charrty and of their incoming resource5 and application of resources. including their income and expendrture. for thal penod. In preparing these financial statemenls, the trustees are required lo". select suilsble accounting policies and then appty them consistentty." observe the methods and principle5 of the charib.es SORP {FRS 1021" make judgments and accounting eslimales that are reasonable and prudent." stale whether appluble UK Accounb"ng Standards IFRS 1021 have been folknved, subject lo any material departures disclosed and explained in the finanual statements. Pfepare the financial statements on the going concem basis unless it is inappropriate to presume Ihal the group will continue in business. The trustees are responsible for keeping adequate accounting records that are sufficient 10 show and explain the group and the Charitys transactions and dI￿10$e wifh reasonable accuracy at any time the financial position of the group and the charity and enable them lo ensure that the financial statements comply with the Companies Act 2006. They are also responsib￿ for safeguarding the assets of the group and the charity and hence for taking reasonable steps for the prèvention and detection of fraud and other irregularities. Approved by order of the members of Ihe boafd of trustees on 24 September 2026 and signed on ils behalf by.. Prof Volker Wilholm Strnub Trustee Page 9

DoDJsvJn Envdope10.. BoC8ÉD2F.F7BM9CM037￿96l IC68D562 Independent auditors. report to the members of TREAT-NMD Alliance Ltd Opinion We have audi(ed the financkal statements of TREAT￿MD Alliance Ltd Ilhe parent Charrtab￿ companYI and its subsidiaries ('Ihe group'l for the period ended 31 December 2025 which ￿MpriSe the consolidated slalemenl of financial aclivitses, the consolidated balance sheet. the charity balance sheet. the w)solidaled slalemenl of cash fl¢)ws and the related notes. including a summary of sKjnrf￿anI accounting policies. The financial feporting framewoth that has been applied in their preparation is appluble law and Unrted Kingdom Accounting Standards, including Financial Reporting Stsndard 102 The Financial Reporting Standard applicable in the UK and Republ￿ of Ireland. (Unrted Kingdom Generalty Accepted Accounting praCt￿e). In our opinion the financial slalements- give a Irue and fair view of the stsle of the group's and of the parent charitable companls affairs as al 31 December 2025 and of the grovp's inctyning resources and application of resources, including its income and expenditure for the period then ended.. have been properly prepared in accordance with United KIngd￿n GeneraNy Accepted Accounting Practice,. and have been prepared in accordance with the requifements of the Companies Act 2006 and the Charities Ac12011. Basis for opinion We conducte(l our audit in accordance IntematKtrnal Standards on Audiling {UK} I'ISAS IUKI'I and applieable law. Our responsibilil*s under those stsndards are further described in the 'Audrtots' responsibilrties lor the audit of the financial slaternents. section of our report. We are independent of the group in accordance with the elhical requirements that are rdevanl to our audii of the ffinanckal statements in the Uniied Kin9dom, including the Financral Reporting Covncifs Ethical Standard, and we have fulfilled our other ethical responsibilities in accordan￿ wrth these requirements. We believe that the audrt evidence we have obtained is suff￿￿nI and appropriate lo provide a basis for opinion. Conclusions relating to going concem In au¢Jiling Ihe financial ststements, we have concluded that the twslees. Ltse of the going concern basis of aceounting in the preparation of the financial slatemenls is appropriate. Based on the work we have performed. we have not Alentsf￿ any material uncertainties relating lo events or condition5 that, indNidually or collectivety, may cast doubt on the group's or the parent charitable company's ability lo continue as a going coneem for a pernd of al least twelve months from when the financial slalements ale aulhorTsed for issue. Our responsibrfilie$ and the responsibilrt￿s of the trustees wilh respect to g￿n9 concern are described in the relevant sections of this report. Page 10

Oo¢usvJn En¥elope ID.. ￿aE02F.F78$8￿8o37￿98I1c68lj562 Independent audltors. report to the members of TREAT￿MD Alliance Ltd (continued) Other Infom)atlon The other information comprises the information included in the annual report other than the financial stslements and our auditors. report the￿on. The trustees are responsible for the other information contained wthin the annual report. Our opini¢)n on the financial stslements (%)es not cover the other information and, except to the extent otherwise expl￿1t￿ slated in our report. we do not express any form of assurance conclusion thereon. Our responsibilily is to read the other information and. in doing $0, consider whether the other infomiation is malerialty inconsistent wrth the financial ststemenls or Ouf knowkdge cbtained in the eourse of the audit, or othe￿ise appears to be materially misstated. If we hdentify such material inconsistencies 01 apparent material misslalemenls, we are requiied to determine whether this gives rise lo a material misstatement in Ihe financial statements Ihemselves. If, based on the work we have performed. we conclude Ihal there is a material misstaterr£nl of this other InfO￿atiOn. vft ae required to report that fact. We have nOth￿g to report in this regard. Opinion on other mattels prescrlbed by the Companies Act 2006 In our OFHnw. based on the work undertaken in the Course of the audit.. the information given in the Trustees. report for the fina￿la1 year for which the finaneial slalemenls are prepared is consistent wrth the financial statements. the Truslees. report has been prepared in aCcorda￿e wrth applicable legal requirements. Matter5 on which we are required to feport by exc•ption In the light of our knowledge and understan(Jing of the charitable company and its environment obtained in the course of the audit, have not ldentrf￿d Materi￿ misstatements In the Trustees, report. We have nothing lo report in respect of the folkM"ng Matte￿ in relation to which Companie5 Act 2006 requires us lo report lo you if. in our Opin￿n.. the parent chantable company has not kept adequate and sufficient accounting rewrds. or returns adequate for our audit have nol been recewed from branches not visited by us". or the parent charitable company financ￿1 statements are in agreement with the accounting reccfd5 and returns., or Certain di￿10$ureS ol Iruslees. remuneration spe¢thed by law are not made,. c we have not received all the information and explanations we require for our audit," or the Iruslees were not entitled to prepa￿ the financkAI stslemenls in accordance with the small companies regime and lake advantage of the small Companies, exemption5 in preparing the Tnjstees. report and frcln the requirement lo p￿p￿e a Strategie report. Page11

Docu5vJn En¥eloF¢ ID.. Btc8E02F.F7B>89C￿￿37￿96l IC68D562 Independent auditors. report to the rnembers of TREAT-NMD Alliance Ltd Icontinued) Respon5ibilitie5 of trustees As explained more fulFy in the truslees. responsibilrties stalenEnt. the trustees (who are also the direetors of the charitable company for the purposes of company Iwl are responsible for the preparation of the financial slalemenls and for being Satisf￿ that they gtve a true and fair view, and for such internal control as the trustees deteimine is necessary to enable the preparalKn of financial statements that are free fr¢)m material misslalement. whether due lo fraud or effor. In preparing the financia statements. the trustees are responsible for assessing the group's and the parent charitsble companvs abilrty to eontinue as a going concern, disclosing. as appl￿ble. malleT5 Telaled lo going concern and using Ihe going concern basis of accounting unless the tnjslees erther intend to liquidate the group or Ihe parent charitable company or lo cease opeTrtKJn5. or have no realistic altemalive bul lo do so. Auditor5. responsibilities for the audit of the financlal ststements Our objectives a￿ to obtain reasonable assurance aboul whether the financial statements as a whole are free from malefial misstatement. whether due to fraud or error. and to issue an auditors, report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audrt Conducted in accordance with ISA5 IUKI will a￿ayS deled a material misslalement when (( exisls. Misslatemenls can arise from fraud or error and a￿ considered material rf. indivhlualty or in the aggrege, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. A further description of our responsibTrlrties for the audrt of the financial sL*emenls is kaled on the Financial Reporting Ccmjncil's website at". Vfv•W.frc.org.ukJaudrt0￿lesponSIbl1th.e5. This description forms part of our audilorfs report_ Extent to which the audit was considered capable of detecting irregularities. including fvaud Irregularities. induding fraud. a￿ instances of non-￿Mpli0nce with laws and regulations. We design pr¢xedures in line wrth our responsibiltti"e5. Outlined above, to detect material misslatemenls in respect of Irregularities. including fraud. The extent to which tsjr PTiJcedures are Capable of deteding irregularities, including fraud is delailetl be￿￿. H￿ever, it is the primary responsibilty of mana9emenl, with the oversight of Ih05e charged wrth g¢)vernance. lo ensure that the enttys operations are conducted in accordance with the provis￿nS of laws and reguL￿"OnS and for the prevents.on and deteckn.on of fraud. We obtain and update our understanding of the Charitab￿ c(xnpany. rts activities. rts control environment, and likely future developments. including in relation lo the legal and regulatory framework applicable and how the charitable company is cOmpl￿ng with that framthvork_ Based on this understanding, we identify and assess the risks of material misstatement of the finan￿al slalements. whether due lo fraud or error, design and perform audf( procedures responsive lo those risks. and rt¢lain audrt evKlerKe that is sufficient and appfopriale to provide a basis for our opinM. Thi5 includes considerats.on of the risk of acts by the entrty that were contrary lo applicable laws and regulations. inclLKling fraud. Based on our understanding of the charitable company, we identif￿d that the principal risks of non-compliance with laws and wulalions relaled lo laws and regU￿tIonS thal directly affect the financial statements including financol reporting legislation (including related companies legislalionl. distributab￿ profils legislation, pension legislation and UK tsx kgislalion. Irb addrt￿n. the ¢haritable company Is subject lo many other laws and regulations where the consequences of non<ompliance could have a material effecl on amounts or disclosure5 in the financial statements, foi inslartce through the imposrtion of fines and Irtigat￿n. We considered the extent lo which non-compliance wrth Ws and regulations mvJht have a material effect on the financial statements and we have as$e5sed the extent of compliance tmth these and regulations a5 part of our procedures on the related financial ststemenl ￿ern$. Page 12

Docuslw En¥elow10: BOc8ED2F_F7Bu9CA-￿37.Eg3I1CG8D562 Independent auditors. report to the members of TREAT-NMD Alllance Ltd (continued) We also evaluated management's incentives and opportun￿"eS for fraudulent manipulation of the financial slalemenls linduding the risk of ovemde of conlrds} and detemiined that the principal risks related lo posting inappropriate journal entr￿$ to manipulate financial resutts. management bias in accounting eslimales, as well as improper income recogn((ion whKh includes fraudulent posting of journal entries lo int￿ne. Audit procedures performed by the engagement team included". . Inquiry of management and those charged 7Mth govemanee regarding xtual and potential hligation or claims as wèll as whether they have knowledge of any actual. suspected or alleged fraud," Reviewng the financial stalement disclosures and tesling to supporting documentation lo assess c￿nplIance th applicable laws and regulations". Rewewing ming minutes to Klenlfy rep￿ted frauds arKI any potential non-compliance wrth laws and regulalion$,' Identifying journal entries based on risk criteria and lesling Ihe ldentrf￿ entries to suppth'ng documentation, in particular joumal entries wrth unusual account combinalDns', and Challenging assumptions and judgments made by management in their swnificanl accounting estimates and evaluating whether there was any evidence of bias by the trustees that r8presenled a risk of material misslatemenl due lo fraud. Because of the inhefent limitalk)ns of an au¢Jit. there 1$ a risk that we will not delecl all irregularities. including those leading to a material misststement in the financial stalements or non-compliance with regulion. This risk increases the more that compliance wth a law or regulat￿n is removed from the events and transactions reflected in the financial slatemenls. as we wll be less likely lo beca￿￿ aware of instances of non-wmpliance. The risk is also greater regarding Ir￿Ul8n11es occurring due to fraud rather than error, a$ fraud involves intentional concealment. forgery. co#usion. omission or misrepresen1at￿n. Use of our report This report is made solely lo the charivs trustees. as a brxly, in accordance wth Chapter 3 of Part 16 of the Compan*s Act 2006. and lo the charrtable companls Iruslees. as a body, Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audrt Wofk has been undertaken so that we might slate lo the charity's trustees those matters we are required to State lo them in an audrtors. report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibilty lo anyone other than the charitable company and its members, as a body. for our audi( work. for this report. or for the opinions VR have fomed. A_ LI￿al s￿orK461F4SE_ Anne Hallowell Bsc DChA FCA (Senior Statutory Auditor) for and on behalf of UNW LLP. Statutory Auditor Chartered Accountants Newcastle upon Tyne 24 September 2026 Page 13

DouJsi9n Envdope ID.. B0C8ED2F-F7B>8￿￿1037-E9&11c68D5S2 TREAT-NMD Alliance Ltd Consolidated Statement of financbal actlvities (incorporating income and expenditure account) Period ended 31 December 2025 Unrestricted Restricted Total Total funds funds funds funds 17 months to 17 months to 17 months to 12 months lo 311)ecember 31 December 31 December 31 July 2024 2025 2025 2025 {as reslaled Note Income from: Grants and donations ChaTilable aetivilies Other trading activities Interest receNable 458.177 458.177 943,565 1,684,821 8.021 114.807 478.182 1,884.343 1,719 943.565 1,684.821 8.021 Total Income 2,636.407 458.177 3.094.584 2.479,051 Expenditure on.. Raising funds Charitable activitie5 2.330.217 316.486 2.330.217 774,663 2.1 $0,531 367,884 458.177 Total expenditure 2.646.703 458.177 3,104,880 2.518,415 Net movement in funds {10,296 (10,2961 139,364} Reconclllatlon of funds: Total funds brought forward Net movement in funds 837.146 {10.296) 837,146 110,296) 876,510 139,3641 Total funds ¢anied fonvard 826.850 826.850 837.146 The notes on pages 18 10 35 fomi part of these finan￿al statements. Page 14

DocuthJTh En¥elcoe ID". B￿8FD2F.F7B>&9CA4037￿g81 IC68D562 TREAT-NMD Alliance Ltd Consolidated balance sheet At 31 December 2025 31 December 2025 31 July 2024 Notg Fixed assets Tangible a5set5 13 18.227 6,596 18.227 6,596 Current assets Debtors Cash at bank and in hand 15 796,426 1.644.122 884,476 1,116,176 2.440,$48 2,000,652 Creditors.. amount5 falling due wthin one 16 {665.790) (1.020.772) Net current assèts 1.774.758 979,880 Creditors.. amounts falling due after more than one year 17 {966.1351 1149.330} Tolal net assets 826.850 837,146 Charity funds Restricted funds 18 unrestr￿ted funds 18 826.850 837,146 Total funds 826,850 837,146 The Iruslees acknowledge their responsibiif(ies for eomplyiry 7*Mh the fequiremenls of the Act %wth respect lo accounting records and preparation of financ￿1 ststements. The financial statements have been prepared in accordance wrth the p￿slOn8 apph'cable to entitie$ Subject to the small companies regime. The financial statements ￿tre approved and aulhofised for issue by the trustees on 24 Seplember 2026 and signed on their behalf by. VdLLY SlrALIl• Prof Volker Wllhelm Straub Trustee The notes on pages 18 to 35 fom) part of these financial statements. Page 15

Dotsjsign ErweloFe ID.. 8oceEO2F.F78>8￿￿037.E98lI¢680562 TREAT-NMD Alliance Ltd Balance sheet At 31 December 2025 31 Decembèr 2025 31 Juty 2024 Note Fixod assets Investments 14 Current assets Debtors Cash al bank and in hand 15 30.250 71.513 38,834 499,811 101.763 538,645 CTedrtors.' amounts falling due wthin one year 16 {92.125) 1529,007) Net currnnt assets 9.638 9.638 Total assets less Current liabilities 9.643 Total net assets 9,643 Charlty funds Restficled funds Unrestricted funds 18 18 9,643 Total funds 9.643 9,643 The companls nel movement in funds forthe perKxI was £nil (2024.. £141.568)1. The Iru$tees acknowledge their responsibiltties for complying ￿th the requirements of the Act with respect lo accounttng records and preparation of financial statements. The financial slalements have been prepared in accordance with the provisKJns applicable to enlth.es subject to the small companEs regime. The finanual slalements were appfoved and authorised for I￿Ue by the tTuslees on 24 September 2026 arbd s￿ned on their behalf by.. V6LLLY Prof Volker Wilhelrn Straub Trustee The notes on pages 18 to 35 fom part of these financial ststements. Page 16

DoDJsi9n Ertvdope ID.. 80C6ED2F-F7B34¥fA4037￿98lle6oDS63 TREAT-NMD Alliance Ltd Consolidated statement of cash flows Period ended 31 December 2025 17 months to31 Decembor 12 months lo 2025 31 July 2024 Note Cash flows from op•rating activities Net cash from operatsng activit￿$ 20 542.778 395.306 Cash flows used In Investing activities Purchase oftsngible fixed assets (14,8321 14.794} Net tash used In Investlng actlvltfjes (14,8321 14.794) Cash flows from financing activities Net cash provided by flnancing activities Change in cash and cash equivalents in the year Cash and cash equNalents at the beginniThJ of the year $27.946 390.S12 1.116.176 725,664 Cash and cash equivalents at the end of the year 21 1,644.122 1.116,176 The notes on pages 18 10 35 fonn part of these financial ststements Page 17

Dovjsign Enve￿)￿ ID." B(uED2F.F7Bu9C￿7.E9811Cfj8D TREAT-NMD Alliance Ltd Notes to the financial statements Period ended 31 December 2025 Ggneral Inforniation The company 1$ a company Iwnbted by guarantee. The members of the company are the trustees named on page 1. In the event of the company being wcyjnd up. the Ikgbility in respect of the guarantee is limited 10 £1 per member of the company. Accounting policies 2.1 Basb of preparntlon of financial statoments The financial statements have been prepared in &cordanee with the Charities SORP IFRS 1021 Accounting and Reporting by Charities.. Statement ol Recommended Practice applicable to charities prepanng their accounts In accordance wrth the Financol Reporting Standard applicab￿ in the UK and Republic of Ireland IFRS 102) (effective 1 January 2019), the Financial Reportiw Standard applicable in the UK and Reputs1￿ of Ireland IFRS 1021 and the Companies Act 21yffj. TREAT-NMD Alliance Ltd meets the definrtion of a public benefrt entrty under FRS 102. Assets and liabilities are inilialty recognised al hsslorical cost or Iransadion value unless otherwise slated in the relevant accounting policy. The current reporting period of 17 months frt>Tr 1 August 2024 10 31 oe￿mber 2025 is longer compared to the prior year reporting peiitrJ of 12 months from 1 August 2023 10 31 July 2024. This is due to the trustees, decision lo extend the reporting period. As such. the comparalwe amount5 presented in the financial statements are not diredy comparabk_ The financial Ststemenls are presented in pounds sterling and rounded lo the nearest pound. 2.2 Basis of Con￿￿ldat10n The consolidated slalemenl of financial activities ISOFAI and consolidated balance sheet consolidate the financial slalemenls of the group and rts subsKliary undertaking. The results of the subsidiary are consolidale(l on a line by line basrs. The group has taken advantage of the exemptKJn allowed under section 408 of the Companies Ad 20(6 and has not presented its own stslement of finanaal athl1￿ in these financial statements. A summary of the charitys result for the period is shcmin in note 11. 2.3 Golng concem The group meets its working capital requirements through its cash balances and operating cash flow5. The trustees have prepared financial forecasts Wh￿h, hawng regard for reasonably possible changes in trading performance as a result of current economic environment. indicate that the charitable group will maintain sufficient financial headroom to enable rt to ccinlinue meeting rts liabilities as they fall due in the normal eourse of business for at least the next months following approval of these financial 5talemenls. At the balance sheet dale, the group held deferred income representing grant funding received in advance of project delivery and assoualed expendrture commilmenls. Forecasts prepared by management demonstrate that the funding currentty secured. toyether with cash reserves and anticipated fvlure grant receipts, will be sufficient lo meet the group's operab.onal and pioject-reiated obligations as they fall due. The trustees have revmved a range of scenari05. including variations in the timing of project expendilure and grant income re￿nitIOn. and are satisfied that adequ*e financial resources are available for the foreseeable luture. Aeeordingty, the trustees continue lo adopt the 90ing concem basis in p￿ paring the financial slalements. Page 18

Dowsign Envdope ID.. 8oC8ED2F-F7B3-89G44037￿98lICB8Dyo2 TREAT-NMD Alliance Ltd Notes to the financial statements Period ended 31 December 2025 Accounting policies Icontlnued) 2.4 Income All income is recognised once the company has enlrtlemenl lo the income, rt rs probable that the income will be received and the amounl of in¢￿￿e receNable can be measured reliabty. Grants are induded in the consolidated slalemenl of financial activities on a receivable basis. The balance of income received for specrfic purposes but not expended during the period is shown in the relevant funds on the balance sheet. Where income is recewed in advance of entitlement of receipt, ils re¢¢gnition is deferred and Induded in credrtors as deferred ineome. Where entitlement occurs before income is received, the income is accrued. Other income is recognised in the peri¢￿￿ in Wh￿ rt is receivable and to the extent the goods have been provKled or on completion of the servti. Trading income comprises revenue rewnised in respect of ser¥Kes supplied during the year, of discounts and excluding Value Added Tax. Trading income is fewgnised as services are provided. Where a contrad ha5 only been partially completed al the balance sheet date, tumovef represents the fair value of the service pTovidecl to date based on the stage of C¢Jmpletion of the contract activity al the balance sheet date. Where payments are feceived from customers in advance of services provided. the amounts are recorded as deferred income and include{ as part of credilors due wrthin one year. 2.5 Expenditure Expenditure 15 recognised once there is a legal or constwctNe obligation lo transfer economic benefit to a third paty. rt is probable that a transfer of economic beneffts wll be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by aclivty. The costs of each activily are fflade up of the lolal of dTrrect costs and Sha￿ costs. including support costs invofved in undertaking each actNty. Direct costs attributable lo a single activty are allocated directly lo that aclivily. Shared costs which contribute to more than one actrvty and sUPPOrt cost5 wh￿h are not allributable to a single aclivty are apportioned between those activrties on a basis consistent with the use of resources. Central staff ¢osls are all0￿?ted on the basi5 of time spent, and deprecialK)n charges allocated on the portion of the asset's use. Expenditure on chantable adiviltes is incurred on direclty undertaing the xtivilies which further Ihft group's objedives, as well as any associated support costs_ 2.6 Employee benefits Short-tem? benefits Short4em beneffts, indudiTh3 hdiday pay and other similar non-monetary benefits, are recognised as an expense in the per￿ in I￿1¢h the servv is received. Defined contn.bulvl￿ pension plan The charitable company operates a defined contribution pensKn pLan for rts employees. Contributions are recognised as an expense when they fall due. kniounls due but not yel paid ale included within creditors on the balance sheet. The assets of the plan are held separalety from the company in independent administered funds. Page 19

Do¢w$ign En%tknF ID. BQC8Eo2F478>8￿8037￿98l IC680562 TREAT-NMD Alliance Ltd Notes to the financial statements Period ended 31 December 2025 Accounting pollcies {eontinued) 2.7 Foreign Currency rransactions and balances Transxlions in foreign currencies a￿ translated into sterling using the spot exchange rates al the dale$ of the Ifansaclions. At each period end. foreign currency monetary assets and liabilities are translated using the closing late. Foreign exchange gains afKJ l¢)sses are reco3nised in the statement of financial acliviljes. 2.8 Tangible fixed assets and depreciation Tangible fixed assets are sLed al cost. less accumulated depreekation and accumulated impairment losses. Cost indudes the original purchase price plus any further costs di￿¢ttY altribulable lo bringing the asset to its working Cond￿on for its interKl&J use. Depreciation is provided on all tangible fixed assets at rates cakulated to write off the cost of fixed assets, less their estimated resKlual value. over their estimed usefvl lives as follows.. Fixtures ar￿ frttings Computer equipment 25% straight line 25% slraight line Asset residual values and useful lives are rewe4ved al the end of eath reportin9 period. and adjusted if appropriate. The effect of any change is accounted for prospeclNely. 2.9 Inv•stments Fixed asset investments are a fomi of financial instrurnenl and are Initial￿ recognised at their transaction cost and subsequentty measured al fair value at the balan￿ sheet date. unless the value cannot be measured reliabty in which case it is measured al cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'GainsllLossesl on investments, in the consolKled stslement of financi￿ actlvrt￿. Investments in subsidiaries are valued at cost less provis¥)n for impaimient. 2.10 Debtors Trade and other debtors are reccgnised at the settlemerrt amount after any IrwJe discount offered. Prepayments are valued al the amunt prepaid net of any trade discounts dLte. 2.11 Cash at b•nk and In hand Cash at bank and in hand indudes cash and short-temi highty liquid investsnents with a short maturity of three months or less from the dale of xquisiti.on or opening of the deposrt or simikr account. Pa9e 20

DOc￿l9n.En¥4Ope ID". BoceE02F.Ff8>89CM037-E9811C680%2 TREAT-NMD Alliance Ltd Notes to the financial ststements Period ended 31 December 2025 Accountlng pollcles (continued) 2.12 Liabilities and provisions Liabilrties are recognised when there is an obligats.on at the balance sheet date as a result ol a past event, is probable that a transfer of econorruc benefit wll be required in settlement, and the amount of the settlement can be estimated reliabty- Liabilities are remgnised * the amount that the cornpany anti¢ipales it will pay to Sett￿ the debt or the amount it has received as advanced payments for the goods or services il musl provKIe. Provistrjns are measurejj at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material. the provision is based on the present value of those amounts, discounted at the pre4ax discount rate that refiects the risks specific to the liabilty. The urwinding of the discount ts rewnised in the consolidated statement of financial 8Ctwities as a finance cost. 2.13 Financial instruments The charrtable gTOUP onty enter5 into basic financial instruments Iransactions that ￿sum in the recognition of financial assets and Irabilrties like trade and other accounts receivable and payable and cash and bank balances. Al such instruments are initralfy recognised at transaCt￿n price. unless the arrangement conslrtutes financing transaction, in which case the tranSa￿￿n is measured al the present value of the future receipts discounted al a market rate of interest. AU ffinancial instrbjnents are subsequently carried al amortised mst usin9 the effective interest rnelhcJ. Z14 Fund accounting General funds are unrestricted lunds which are available for use at the discretion of the Iruslees in furtherance of the general oty'ectives of the group and wh￿h have nol been designated foi other purposes. Restricted funds are funds which we to be used in accordance wth specifTrc restricltons imposed by donors or which have been Taised by the group for part￿lar PUTposes. The costs of raising and administering such fvnds are charged against the specifc fund. The aim and use of each restri¢led fund is $91 out in the rbotes to the financk31 statements. Investment income. gains and bsses are alk)cated to the appropriate fund. Critical accounting estimates and areas of judgrnent Estimates and judgments are continualty evaluated and are based on historical experience and other factors. induding expectations of future events th are believed to be reasonable under the Circumstances. In preparing these financial statements the tnjstees do not consider there were any si9nrfi¢anl areas of judgment or aceounling eslimales, other than those noted below that were required m apptying the group's accounlmg policies as set out atw)ve. Deferred income A significant judgement has been made in determining the amourrt of grant funding that should be deferred at the reporting date. Funding received for the PaLaDln project is subject lo reStr￿IK)nS and future perfomiance obligatkjns and. accordingly. amounts reLats"ng to future project activitie5 have been recognised as deferred income until the a550ciated costs are incurred and rekvanl condition5 are met. Page 21

Docu$KJn Envel)k*10". 8tCeED2F￿7B>a9C￿Wj7.E98I1C68OSfj2 TREAT-NMD Alliance Ltd Notes to the financial statements Period ended 31 December 2025 Income from grants and donalions Restrictèd Total funds funds 17 months 17 months to31 to31 December December 2025 2025 PaLaDln proieet grant 458,177 458.177 Re5trided funds 12 months to 31 July 2024 las restated) Total fund5 12 months 10 31 July 2024 las reslatedl PaLaDln project grant 114,807 114,807 The comparalNe ffigures in these finanual statements have been reslaled lo reclassify the group's income and associated expendriure relating to funding received by the group's subsidiary undertaking in the prior year in respect of a PaLaDln project grant_ Income from grants and donations together with expenditure on chafitable aclmties have been increased by £114,807. wrth corresponding reductions in income from other trading aclivrties and expendiluie on raising funds. respedively. The Iruslees cgnstder that Ihis reslalement. together wrth classification of the grant weipls and related expenditure within restricted rather than unrestricted funds, more appropriately refflect5 the nature and terms of the project to which these transactions relate. This restatement does not have any effect on the group's movement in reslricled or unrestricted funds nor on the group's tolal funds, as previously reported. Income from charitable activities Unrestricted Total funds funds 17 months 17 months to31 to31 December De¢emb•r 2025 2025 Educalional activrties income 943.565 943,565 Page 22

Docuslw Enw8l¢pe ID.. WK8Eo2F.F78￿Th8O37.E9Bl1¢68D562 TREAT-NMD Alliance Ltd Notes to the financial statements Period ended 31 December 2025 Income from chaiitable activities (continu￿) Unreslricled funds 12 months to 31 July 2024 Totsl funds 12 months 10 31 July 2024 Educaltr?nal activities inccffie 478.182 478,182 Income from other trading activities Income from non charltable Irading activities Unrestricted funds 17 month5 to31 December 2025 Total funds 17 months to31 December 2025 Project income 1.684,821 1.684,821 Unrestricted funds 12 months to 31 July 2024 {as restaledl Total funds 12 months 10 31 Juty 2024 las reslaled) Project income (see note 4) 1,884.343 1,884,343 Page 23

DooJ$iyn Envelope K).. BCC8E02F_F78>8KU037.E9811C68D562 TREAT-NMD Alliance Ltd Notes to the financial statements Period ended 31 December 2025 Intsrest recelvable Unrestricted funds 17 month5 to31 December 2025 Totsl funds 17 months to31 December 2025 Interest receivable 8.021 8.021 un￿StriCted funds 12 months to31 Juty 2024 Totsl funds 12 months to31 July 2024 Interest receivable 1.719 1.719 Expenditure on raising funds Stsbsidiary tiading expenses Unrestricted funds 17 months to31 December 2025 Total funds 17 months to31 December 2025 Cost of sales Exceptional administfalive expenses Administration expenses Tax credrt Administrative staff eosls 168.291 11,907 622,551 134,050) 1,%1.518 168,291 11,907 622,551 (34.0501 1,561,518 2,330,217 2,330,217 Page 24

OrKuwgnEn¥dy ID.. 8OC8ED2F.F7834KA4037￿9B11¢fjeO£62 TREAT-NMD Alliance Ltd Note5 to the financial statements Period ended 31 December 2025 Expenditure on raising ￿Trds Icontinuedl Unrestricted fvnds 12 morblhs 10 31 July 2024 (as restsled) Total funds 12 months to 31 July 2024 {as restsledl Cost of sales (see note 41 Adminislr8l•Jn expenses Tax credit Administrative staff costs 733,994 426,892 (12.8981 1,002,S43 733,994 426,892 112,8981 1.002,$43 2,150,531 2.150,531 Analysis of expenditure by activities Support Total DIr￿t costs Costs funds 17 Months 17 months 17 months to31 to31 to31 December December December 202S 2025 2025 Educational actiwty costs PaLaDln pfoject costs 301.799 458,177 14,687 316.486 458.177 759.976 14,687 774,663 Adivknes undertaken directly 12 months 10 31 July 2024 las reslaledl Support costs 12 month$ to 31 July 2024 las resl*ed) Total funds 12 month$ 10 31 July 2024 las reslaledl Edu¢ational actimty cost$ PaLaDln project costs (see note 41 239,215 114.807 13.862 253.077 114,807 354.022 13,862 367,884 Page 25

DO￿Srgn Énvelope ID.. 80C8ED2F-F78>89CMO37￿9e1lcoaD5S2 TREAT-NMD Alliance Ltd Notes to the financial statements Period ended 31 December 2025 Analysis of expenditure by activities {continuedl Analysis of support costs Total funds 17 months to31 December 2025 Total funds 12 months 1031 Juty 2024 Office costs Bank fees Legal fees Foreign exchange losses 11.387 1.360 504 1.436 7.493 871 4,303 1.195 14,687 13.862 10. Auditors. remuneration 2025 2024 Fees payable to the chantable ¢ompanY$ auditor for the audit of the charrtable CoMpan￿S annual accounts 13.650 13.000 11. Charitable company results The results of the charrtable company are sh¢ywn belcMT". 17 months to 31 12 months D￿ember to 31 July 2025 2024 Income Expenditure Surpluslldeficit) 943.$65 478,182 ) 7501 All funds were unrestrttted during the year. Page 26

DocusignEn¥*fope ID.. 80C8ED2F.F7B>8StA4O37￿9&lIC68O562 TREAT-NMD Alliance Ltd Notes to the financial statements Period ended 31 December 2025 12. Staff costs D•cernber2924 15 wiod) D•c•rnlRr2025 qA2 month periodl 2024 112 m•nth perfodl 117 month periodl Wages and salarie5 &)clal securitycosts Corrtributlonto defined penslon scheme5 L340.526 15BJ 43252 115.048 92.718 15.ffi2 L116,019 1.561,518 L002.543 The chaTitable company ITREAT-NMD Alliance Ltd) has no staff costs or employees (2024.. nill. The average number of persons empbyed by the charitatk group (wrthin TREAT-NMD Services Ltd) during the periotlfyear was as fdl¢yws.' Group 2025 No. Group 2024 No. 19 19 The number of employees whose empbyee benefits (excluding empwr pension costs) exceeded £60.000 was.. Group 17 months to31 Decembei 2025 No. Group 12 mnths to31 July 2024 In the band £60,(K11 - £70.000 In the band £70,001- £80.000 In the band t90,001- £100.000 In the band £100,001 - £110,000 In the band £160,th)1 - £170.000 In the band £240.fy)1- £250.000 Page 27

DocusvJTh En¥eknpe10.. 8Lf8ED2F.F7B>8U8037.E9811C68D562 TREAT-NMD Alliance Ltd Notes to the financial statements Period ended 31 December 2025 12. Staff costs {¢ontlnuedl The current reporting pell.od eovers 17 months 11 August 2024 to 31 December 20251. Comparatives relate to a 12 month per#)J. Employee remuneration is disclosed based cffi lolal rernuneralion earned within each respeclive period. The key management personnel of the Charitable group comprise.. CEO CEO Headoloperations HeadolCentralSer4tces RealWoFidEwdefKe Manager DataGts%mare Marr Head ol Educatlon & Errts Busine555upportManagei RealWoTld ENryde￿e Manager Dats Manager The total emth benefits of the key management personnel of the charitable group were as folk)ws'. A*5ttoDeremb¢T J•nu•ryto Deremkn 2W25{17mgRth 20U{12morth 2tr24{Srno￿h pefivdl 2025112rnDAthwiodl pwiodl p¢riodl Totsl 139.878 7.705 507,5&3 Page 28

DLKU51gn Envelope ID". 80C8ED2F.F7B>8W037.E9811C68D562 TREAT-NMD Alliance Ltd Notes to the financial statements Period ended 31 December 2025 13. Tangible fix¢d assets Group Fixtures and fittin95 Computer equipment Total Cost At 1 August 2024 Addfiions 17.397 12.763 19.261 14,832 2.069 At 31 December 2025 3,933 30.160 34,093 Depreciation At 1 August 2024 Charge for the peTic*J 11.778 2.789 12,665 3,201 412 At 31 Decefflber 2025 1,299 14.567 15,866 Net book value Al 31 Deeember 2025 2.634 15,S93 18.227 977 5,619 6,596 Al 31 Jufy 2024 Page 29

DocusvJn En¥*kJpe ID". BOc8E02F.F7B&89CU037￿8•Ic6005O2 TREAT-NMD Alliance Ltd Notes lo the financial statements Period ended 31 December 2025 14. Fixed asset investments Investrnents in subsidiary companies Cornpany Cost Al 1 August 2024 Al 31 Deeember 2025 Net book value Al 31 December 2025 Al 31 Juty 2024 Principal subsidiari8s The followin9 was a subsidiary undertaking of the charity. Name Company number Registered office or principal place of businwss Class of shares Holding Included in consolidation TREAT.NMD Services Ltd 12110979 The Spark Drayrnans Way Newcastk Helix Newcastle Upon Tyne England NE4 5DE Ordinary 10N Yes The financial resums of the subsidiary fof the period were". Name Income Expenditure Prof•Ulloss) for the year Net ass8ts TREAT-NMD SeNces Ltd 2.812.148 (2.822.444Tr 110.2961 817.212 P•3e 30

Oor)J*Jn ETh¥e￿pe ID". BLf8E02F.F7B>8Th803749811C690562 TREAT-NMD Alliance Ltd Note5 to the financial statements Period ended 31 December 2025 15. Debtovs Group 2025 Group 2024 Charity 2025 Charity 2024 Trade debtors Olher debtors Prepayments and acenjed in￿￿ Deferred tsx VAT recoverable 258.668 609. 2,373 226.841 3,307 41.987 15,000 10.000 532.032 15,249 28.271 5.726 563 796.426 884.476 30,250 38,834 16. Croditors: arnounts falling due within one year Group 2025 Group 2024 Charity 2025 Charity 2024 Trade creditors Amounts owed to group urthrtakings Other laxalKJn and So￿al wurty Other creditors Accruals and deferred income 119.591 174,332 750 169.631 76.884 15.241 38.780 7.621 499,798 28.955 12.282 805,203 358,626 665.790 1.020.772 92.125 529,007 Group 2025 Group 2024 Charity 2025 Charrty 2024 Deferied income at the beginning of the peri¢xl Resources deferred during the year Amounts Teleased from prev￿￿$ perwjds 954,S33 1,296.Q72 1804.200) 294,327 954,533 {294,327} 358,626 358.626 {358.626) 1.446.405 954,533 358,626 PwJe 31

tlotJJswJfi Envelope ID.. 80c8EO2F.F7BM￿o037.E9&11C08OS62 TREAT-NMD Alliance Ltd Notes to the financial statements Period ended 31 December 2025 17. Creditops: amounts falling due after more than one year Group 2025 Group 2024 Accruals and deferred income 966,13S 149.330 A￿r￿al$ and deferred incorre relales lo a granl reeeipl receive(I during the periodtyear. which is rin9fenced for future expenditure on the PaLaOln project and is held in a separate bank account. 18. Statement of funds SlateTrient of funds- current year Balance at 31 December 2025 Balance at 1 1 August 2024 Income Expenditure Unrestricted funds General Funds 837.146 2,636.407 {2,646.7031 826.850 . Restrlcted funds PaLaDln Proj 458.177 1458.1771 Total of funds 837.146 3.094.584 13.104.880) 826,850 Statement of funds - prior year Balance at Balance at 1 August Income las Expendrture 31 July 2024 2023 restaledl {as restated) las reslaledl Unrestricted funds General Fund5 (see note 4} 876.S10 2,364.244 {2.403,608) 837,146 Restrlcted funds PaLaDln Pro1￿t (see rK>te 4} 114,807 1114,807) Total of fund5 876,510 2,479,051 (2.518.415} 837.146 Page 32

Docusiw Fn¥eloF ID.. BoceED2F.F7B3-89CA4037E9811C68D562 TREAT-NMD Alliance Ltd Notes to the financlal statements Period ended 31 December 2025 19. Analysis of net assets between funds Analysis ol net assets between funds- current year Unrestricted Restricted fund5 funds 2025 2025 Total funds 2025 Tangible fixed assets Current assets Creditors due wthin one year Cre￿￿orS due in more than one 18,227 1,474.413 1665,7901 18,227 2.440,548 1665,790 1966,1351 966,135 I￿.135) Total 826,850 826,850 Analysis of net assets between funds - prior year Unrestricted funds 2024 las reslaled) RestrKled funds 2024 las restated) Total funds 2024 (as restated) Tangible fixed assets Current assets Creililors due within one year Creditors due in more than one year 6.596 1,851.322 11.020.772) 6.596 2,000,652 11,020.7721 1149.3301 149.330 1149.3301 Total 837.146 837,146 The pric year figures for current assets arKI creditors due in more than one year. as shown above, have been reslaled lo recognise £149,330 of grant monies wthin restrKtsd fLtnds, rather than unrestrided fund5 as previously reported Isee note 4 for further details}. Page 33

OotsJsvJn En¥elope ID.. 8OC8ED2F-F7BM9CA-8037.E9811WD TREAT-NMD Alliance Ltd Notes to the financial statements Period ended 31 December 2025 Reconciliation of net movemenl in funds to net cash flow from operaling a¢ti¥itbes Group 17 months Group to 31 12 months December 10 31 July 2025 2024 Nel expendilure for the perK#Jfyear las per SL*ement (rf Finaneial Activities 110,2961 139,3641 Ad5ustments for. DepreCiat￿n charge5 Decrea$el{increase} in debtors Increase in creditors 3.201 88.051 461,822 4,262 {298,6621 729,070 Net cash from operatlng acllvllies $42,778 395,306 21. Analys55 of cash and Cash equlvalents Group 2025 Group 2024 Cash in hand 1.644.122 1,116,176 The cash balance of £1.644.122 inckKle5 8 granl ￿elp1 of £966,135 (2024.. £149.3301 which is ringfenced for fulure eXPendrtu￿ and is included in deferred income. 21 Analysls of changes in nel debt At31 December 2025 At I Au9USt 2024 Cash flows Cash at bank and in hand 1,116.176 527.946 1,644.122 23. Pension commitments The group operates a defined contributions pension scheme. The assets of the scheme are held separalety from those of the group in an independent￿ administered fund. The pension cost charge represents contributions payable by the c¢)mpany lo the fund and amounted 10 £62,69212024." £36,873). Contributions lotalling £7,621 12024.. £3,467) were payable lo the fund al the balance sheet dale and are included in cred((ots. Page 34

DocU￿9n Envd¢pe ID.. Bt(8ED2F_F￿89CAW37￿811c6fjOS62 TREAT-NMD Alliance Ltd Notes to the financlal statements Period ended 31 December 2025 Relat•d party transactlons During the perwjd honoraiium payTnents totalling £nil {2024.. £734) were paid to J Dowling. ex- tru$tee. for attendance al TACT meetsngs. During the period reimbursements totalliNJ £1.94912024'. £nif) were paid to K Wagner. chair and trustee, for travel. During the year honorarium payments lotslling £nil {2024: £500) were paKI to A Oe Luca, ex- trustee, for attendance at TACT meetings. During the perio￿. payments of £nil (2024.. £27.2321 were paid lo Muscular Dystrophy Association USA. charity in whKh S Hesterlee, a director of Treal-NMD Servtts Lwnited, has significant influence. in relation lo a gene therapy mastefclass. During the period, payments totalling £1,581 12024." £7.0001 were paKI to Newcastle University. an organisation wlh signffieanl influence. in relalKJn to honorariums to conlribulors and project participation fees. Page 35